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Background. Previous studies have shown impaired fibrinolysis in multiple sclerosis (MS) and implicated extracellular proteolytic
enzymes as important factors in demyelinating neuroinflammatory disorders. Tissue-type plasminogen activator (t-PA) and its
inhibitor (PAI-1) are key molecules in both fibrinolysis and extracellular proteolysis. In the present study, an association of the TPA
Alu I/D and PAI-1 4G/5G polymorphisms with MS was analyzed within the Genomic Network for Multiple Sclerosis (GENoMS).
Methods.TheGENoMS includes four populations (Croatian, Slovenian, Serbian, and Bosnian andHerzegovinian) sharing the same
geographic location and a similar ethnic background. A total of 885 patients and 656 ethnically matched healthy blood donors with
no history of MS in their families were genotyped using PCR-RFLP. Results. TPADD homozygosity was protective (OR= 0.79, 95%
CI 0.63–0.99, 𝑃 = 0.037) and PAI 5G5G was a risk factor for MS (OR= 1.30, 95% CI 1.01–1.66, 𝑃 = 0.038). A significant effect of the
genotype/carrier combination was detected in 5G5G/I carriers (OR= 1.39 95% CI 1.06–1.82, 𝑃 = 0.017). Conclusions. We found a
significantly harmful effect of the combination of the PAI-1 5G/5G genotype and TPA I allele on MS susceptibility, which indicates
the importance of gene-gene interactions in complex diseases such as MS.
1. Introduction
Multiple sclerosis (MS) is a complex inflammatory demyeli-
nating disease of the central nervous system (CNS) with both
genetic and environmental contributing factors.The underly-
ing cause of the disease is thought to be the cumulative effect
of multiple genetic variants throughout the genome, each
making amodest contribution to the onset and progression of
the disease. However, despite great progress in detecting risk
loci for MS using high-throughput technologies over the last
decade [1], much remains to be discovered about the genetics
of MS [2].
In recent years, increasing evidence has pointed to the
potential role of fibrinolysis in the pathogenesis of MS.
Specifically, the characteristic inflammation, focal demyeli-
nation, and axonal degeneration inMS occur after disruption
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Table 1: Characteristics of MS patients.
Parameter Serbian (𝑛 = 382) BH (𝑛 = 170) Croatian/Slovenian (𝑛 = 333) Pooled samples (𝑛 = 885)
Gender (female/male) 241/141 (63.1/36.9) 120/50 (70.6/29.4) 239/94 (71.7/28.3) 600/285 (67.8/32.2)
Age of disease onset (years) 29.2 ± 7.0 30.8 ± 8.0 29.4 ± 8.9 30.1 ± 8.0
MSSS 5.4 ± 2.5 4.8 ± 2.8 4.9 ± 2.7 5.2 ± 2.6
MSSS: Multiple Sclerosis Severity Score.
Values are expressed as mean ± SD.
of the blood-brain barrier (BBB) and entry of serum pro-
teins, including fibrinogen, into the CNS [3]. Extracellular
proteolysis represents a potent and irreversible mechanism
modulating the extracellular matrix and tissue remodeling,
which can affect the breakdown of the BBB. Extracellular
proteolytic enzymes have been implicated as important fac-
tors in demyelinating neuroinflammatory disorders such as
MS [4]. The enzymes of the plasminogen activators/plasmin
(PA) system are involved in both fibrinolysis and extracellular
proteolyses.
The key molecules in the PA system are tissue-type
plasminogen activator (t-PA) and its inhibitor (PAI-1). Due to
the formation of t-PA and inhibitor (e.g., PAI) complexes, the
fibrinolytic potential in demyelinating MS lesions is greatly
diminished [5]. The limited availability of t-PA because of
the formation of the t-PA/PAI-1 complexes is assumed to
reduce the ability of t-PA receptors to produce plasmin,which
further diminishes the fibrinolytic capacity in MS lesions,
possibly resulting in increased axonal fibrin deposition and
neurodegeneration [6, 7]. On the other hand, itmay represent
a mechanism to remove fibrin deposits, which are then
cleared through internalization by macrophages.
In experimental autoimmune encephalomyelitis (EAE),
deletion of the TPA gene results in an earlier appearance
and more severe form of disease associated with high levels
of PAI-1 and inefficient fibrin removal [7]. Recent studies
have shown that the PAI-1− knockout (PAI-1−/−) mice have
reduced disease incidence, a milder clinical picture, lack of
clinical relapse, and reduced neuroinflammation, as well as
less axonal damage than wild-type (wt) mice [8].
An Alu-repeat insertion/deletion (I/D) in intron 8 of
the TPA gene and the 4G/5G polymorphism in the 5󸀠-
untranslated region at −675 of the PAI-1 gene are known, as
are differences in the productivity of these proteins between
genotypes. The t-PA release rates were markedly higher in
subjects homozygous for the I allele [9], whereas individual
homozygous for the 4G allele has a 25% higher plasma PAI-1
concentration than those with the 5G5G genotype [10].
To date, only two studies have investigated the correlation
between these polymorphisms and MS [11, 12].
Because of technical limitations, the insertion/deletion
polymorphism could not be analyzed in recent GWAS
studies.
The aim of the present study was to investigate the role
of the TPA I/D and PAI-1 4G/5G polymorphisms in a new
MS study population andperformameta-analysis of previous
studies [11, 12].This study was conducted within theGenomic
Network for Multiple Sclerosis (GENoMS), which includes
four populations (Croatian, Slovenian, Serbian, and Bosnian
and Herzegovinian [BH]) that share the same geographic
location and a similar ethnic background, a Slavic origin.
2. Materials and Methods
2.1. Subjects. Cohorts of MS patients collected in Serbia and
BH were included in the study. All patients fulfilled the
criteria for clinically definite MS [13] and the course of the
disease was classified based on clinical data [14]. Patients
with relapsing-remitting (RR) or a secondary progressive
(SP) course were grouped as bout-onset and analyzed sepa-
rately from patients with the primary progressive (PP) form.
Disease severity was estimated using the Multiple Sclerosis
Severity Score (MSSS) [15], which corrects the Expanded
Disability Status Scale (EDSS) [16] for disease duration.
A total of 382 Serbian patients (141males and 241 females)
were recruited from the Department of Neurology of the
Military Medical Academy (MMA), including 372 (97.4%)
patients with bout-onset MS and 10 (2.6%) with PPMS. The
mean age at onset was 29.2±7.0 years and themeanMSSSwas
5.38 ± 2.52. The Serbian controls were 318 healthy volunteers
without a history of MS in their families and of the same
ethnic origin as the MS patients.
The BH dataset consisted of 170 patients (50 males and
120 females) recruited consecutively from the Department
of Neurology, School of Medicine, University of Mostar and
Department of Neurology, School of Medicine, University
of Tuzla, and 170 healthy volunteers of matched ethnicity
(Bosnians, Croatians, Serbians). Among the patients, 160
(94.1%) had bout-onset MS and 10 (5.9%) had PPMS. The
average age at onset was 30.8 ± 8.0 years and the mean MSSS
was 4.79 ± 2.81.
For pooled analyses, we included the Croatian and
Slovenian subjects, which were the study groups used in a
recently published study [12]. The 333 MS patients (94 males,
239 females), including 308 (92.5%) with bout-onset MS and
25 (7.5%) with PPMS, had a mean age at onset of 29.4 ± 8.9
years and meanMSSS of 4.94 ± 2.73. A total of 368 ethnically
matched healthy blood donors with no history of MS in their
families represented the control group.
Table 1 provides a description of the MS groups included
in the study.
2.2. Genotyping. Genomic DNA was extracted from whole
blood using standard procedures. Genotypingwas performed
in the Molecular Genetics Laboratory (Department of Biol-
ogy and Medical Genetics, School of Medicine, Rijeka) using
PCR (for the TPA Alu I/D polymorphism) or PCR-RFLP
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(for the PAI-1 4G/5G polymorphism) as described previously
[9, 17].
2.3. Statistical Analysis. Statistical analyses were carried out
using Statistical Software package for Windows 7.1 (StatSoft,
Inc.). Differences in the allele and genotype frequency dis-
tribution between the studied groups, as well as deviation
from Hardy-Weinberg equilibrium, were estimated by the
chi-square (𝜒2) test. A logistic regression analysis expressed
in terms of an adjusted odds ratio (OR), and 95% confidence
interval (CI) was used as a measure of the strength of
the association between the TPA I/D and PAI-1 4G/5G
polymorphisms and susceptibility to MS.
To assess the relationship between studied polymor-
phisms and MS, we performed a meta-analysis of the four
datasets, comprising Serbian, BH, Croatian, Slovenian [12],
and Finnish subjects [11]. Subjects were classified by diag-
nostic category (patients and controls) and number of events
(the presence of the PAI-1 5G5G genotype or the presence
of the PAI-1 5G5G/TPA I carrier combination). The strength
of the association was summarized using the OR in which
PAI-1 5G5G homozygosity or PAI-1 5G5G/TPA I carriership
was assigned as a risk factor for MS. Each of the cohorts was
analyzed separately, and the significance of the pooled ORs
was determined using the 𝑧-test. The heterogeneity of the
group of ORs was assessed using the 𝜒2-based𝑄-statistic test.
Meta-analyses were conducted using Comprehensive Meta-
Analysis software version 2.0 (Biostat International, Inc.).
Analysis of variance (ANOVA) and appropriate post
hoc tests were used to test the relationships between the
polymorphisms and continuous variables. In all of the tests,
differences with two-tailed 𝑃 ≤ 0.05 were considered
significant. Multivariate regression analysis was performed
to assess the influence of genetic and clinical parameters on
disease onset, clinical course, and MS progression.
2.4. Ethics Statement. The study was approved by the respec-
tive local ethics committees in all countries participating in
the study: Ethics Committee of the MMA, Serbia (reference
number: 29/2-05), Ethics committee of the Clinical Hospital
Mostar (reference number: 3590/07), the Ethics commit-
tee of the University Clinical Hospital Tuzla, Bosnia, and
Herzegovina (reference number: 01/3-37-4-7683/07), Ethics
committee at School of Medicine at University of Rijeka,
Croatia (reference number: 641-01/06-01/66), and the Slove-
nian National medical ethics committee (reference number:
90/08/12). All participants signed awritten informed consent.
For those patients who have had a compromised capacity to
consent (Folstein Mini-Mental State Examination (MMSE)
score below 20) informed consent was signed by the nearest
relative or guardian.
3. Results
3.1. TPA I/D and PAI-1 4G/5G Genotypes and Alleles in MS
Patients and Controls. The Serbian and BH case-control
groups were analyzed separately and also pooled with Croa-
tian and Slovenian samples [12] following the demonstration
of a lack of significant heterogeneity. The distributions of
allele and genotype frequencies are provided in Table 2. The
genotype distributions amongMS patients and controls were
compatible with Hardy-Weinberg expectations for both the
Serbian and BH cohorts. In the Serbian cohort, PAI-1 5G5G
homozygosity (OR = 1.54, 95% CI 1.04–2.28, 𝑃 = 0.032)
was positively associated with MS, and 4G5G heterozygosity
(OR = 0.68, 95% CI 0.50–0.92, 𝑃 = 0.012) was negatively
associated with MS compared to controls. The distribution
of the TPA I/D polymorphism was not significantly different
in patients compared to controls in the Serbian group. No
significant differences were found in the genotype and allele
frequency distribution for the polymorphisms in BH patients
and controls.
3.2. TPA I/D and PAI-1 4G/5G Genotypes in Pooled MS
Samples andMeta-Analysis. Comparisons of allele and geno-
type frequencies between pooled MS patients and controls
(Serbian, BH, Croatian, and Slovenian, Table 2) did not reveal
significant associations, but we found a trend towards a
decreased risk of MS in patients with the TPA DD genotype
(OR = 0.80, 95% CI 0.65–1.00, 𝑃 = 0.050) and an increased
risk of MS in patients with the PAI-1 5G5G genotype (OR =
1.27, 95% CI 0.97–1.61, 𝑃 = 0.054).
Although the crude association of the TPA and PAI-1
polymorphisms with MS in a pooled sample (Serbian, BH,
Croatian, and Slovenian) did not reveal a significant associa-
tion after adjusting theORs for gender, the TPADD genotype
was shown to be significantly protective (OR = 0.79, 95% CI
0.63–0.99, 𝑃 = 0.037) and the PAI-1 5G5G genotype was
shown to be a significant risk factor (OR = 1.30, 95% CI
1.01–1.66, 𝑃 = 0.038) for MS (Figure 1). The meta-analysis,
which also included the results from a Finnish study [11],
confirmed the significant risk for MS among PAI-1 5G5G
homozygotes (OR = 1.33, 95% CI 1.06–1.67, 𝑧 = 2.450, 𝑃 =
0.014, 𝑃heterogeneity = 0.143; Figure 2) compared to the carriers
of the 4G allele.
3.3. Combination of TPA I/D and PAI-1 4G/5G Genotypes
in Pooled MS Samples and Meta-Analysis. We analyzed the
genotype combinations and/or allele carriership for the TPA
I/D and PAI-1 4G/5G polymorphisms in a pooled study sam-
ple. The frequency analysis of these combinations is shown
in Table 3. The only significant effect of the genotype/allele
carrier combination was detected in 5G5G/I carriers (both
of these polymorphisms separately carry a significant risk for
MS), with an even higher and more significant OR for MS
than in the separate analysis (OR = 1.39 95% CI 1.06–1.82,
𝑃 = 0.017). The meta-analysis confirmed this result (OR =
1.38, 95% CI 1.05–1.82, 𝑧 = 2.328, 𝑃 = 0.020, 𝑃heterogeneity =
0.102; Figure 3).We did not find a significant difference in the
distribution of the genotypes and alleles of the tested genes
after stratifying by gender.
3.4. TPA I/D and PAI-1 4G/5G Genotypes and Clinical Char-
acteristics of MS. We did not find a significant association
between the separate or combined effects of the TPA I/D
or PAI-1 4G/5G genotypes and disease course (bout onset
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Figure 1: The separate effects of the PAI-1 5G/5G and TPA D/D genotypes on MS susceptibility in a pooled sample of 885 MS patients. Data
are presented as the OR adjusted for gender. The error bars represent the 95% CI. TPA D/D, OR = 0.80, 95% CI 0.65–1.00, 𝑃 = 0.050; PAI-1
5G/5G, OR= 1.27, 95% CI 0.97–1.61, 𝑃 = 0.054.
Populations Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit
Serbian 1,538 1,039 2,276 2,149 0,032
Bosnian and Herzegovian 0,779 0,461 1,317 0,351
Croatian and Slovenian 1,369 0,932 2,010 1,601 0,109
Finish 1,798 0,962 3,361 1,838 0,066
1,328 1,058 1,666 2,450 0,014
0,01 0,1 1 10 100
Favours A Favours B
−0, 933
Z-value P value
Figure 2: Meta-analysis of the four case-control studies of MS and the PAI-1 4G/5G polymorphism. Comparisons were made between the
5G5G and 4G4G+4G5G genotypes. Summary ORs and respective 95% CIs were calculated using the fixed-effect model.
versus PP), age at disease onset, or MSSS in the Serbian and
BH patient samples separately, or in a pooled sample of MS
patients (data not shown).
4. Discussion
In this study, we analyzed the influence of the TPA I/D and
PAI-1 4G/5G polymorphisms on MS. We found a significant,
but opposite, influence of the rare TPA and PAI genotypes on
MS susceptibility. The TPA D/D genotype had a protective
effect, whereas PAI 5G/5G was a risk factor for MS. The
meta-analysis for the PAI-1 polymorphism, which included
the previously published results [11], confirmed that 5G/5G
represents a significant risk factor for MS.
The investigated polymorphisms have been investigated
predominantly in vascular disorders [18], rather than diseases
such as MS. The single alleles (e.g., 4G) have been found
to have opposite effects in cardiac disease (increased risk)
compared to brain ischemia (protective effect).
The 4G allele has been linked to higher serum levels of
PAI-1 [10]. Recent data suggest a functional importance of
the PAI-1 4G/5G polymorphism, which could have a neu-
roprotective effect through increased astrocytic expression
of PAI-1 [19]. Haplotypes containing the PAI-1 4G allele
have been associated with higher transcriptional activity in
astrocytes compared to haplotypes containing 5G [19]. In
this study, the 5G5G genotype exhibited a 1.3-times higher
risk for MS susceptibility compared to 4G carriers. In a
previous study of Finnish women with MS [11], the 5G5G
genotype, which is linked to lower plasma levels of PAI-1 [10],
was associated with an increased risk of MS. These results
show a consistency in the neuroprotective role of sufficient
PAI-1 in the brain through allele-specific regulation of its
presence. In addition, the PAI-1 gene is located in the MS
susceptibility locus on chromosome 7q21-22 [20]. Only two
studies previously looked at the association with MS [11, 12],
and GWAS lack data on insertion/deletion polymorphisms,
such as the two investigated here.
In the brain, PAI-1 is produced predominantly by astro-
cytes [21], whereas its main function is to inhibit t-PA [22].
After injury, an excessive amount of t-PA is released into
the extracellular space of the brain, which can trigger both
neuronal degeneration [23] and disruption ofthe BBB [24].
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Table 3: The uncorrected odds ratios (ORs) for combination genotypes of the TPA I/D and PAI 4G/5G polymorphisms in MS patients and
controls.
Genotype combinations MS patients (𝑛 = 885) Controls (𝑛 = 856) OR (95% CI) 𝑃
PAI 4G4G/TPA DD 58 (6.6%) 71 (8.3%) 0.78 (0.54–1.1) 0.167
PAI 5G5G/TPA DD 39 (4.4%) 38 (4.4%) 1 (0.63–1.57) 0.974
PAI 4G carrier/TPA DD 161 (18.2%) 185 (21.6%) 0.81 (0.64–1.02) 0.074
PAI 5G5G/TPA I carrier 144 (16.3%) 105 (12.3%) 1.39 (1.06–1.82) 0.017
Populations Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit
Croatian and Slovenian 1,510 0,974 2,339 1,844 0,065
Serbian 1,745 1,119 2,719 2,458 0,014
Bosnian and Herzegovian 0,805 0,451 1,436 0,462
1,385 1,053 1,823 2,328 0,020
0,01 0,1 1 10 100
Favours A Favours B
−0,736
Z-value P value
Figure 3: Meta-analysis of the three case-control studies of MS and the PAI-1 4G/5G and TPA I/D polymorphisms. Comparisons were made
between the PAI-1 5G5G/TPA I carriers and other genotype/carrier combinations. Summary ORs and respective 95% CIs were calculated
using the fixed-effect model.
Thus, PAI-1 is needed to reduce the deleterious effects of
excessive t-PA activity. An increase in brain damage has been
shown in PAI-1-deficient mice [25].
In themousemodel ofMS, EAE, t-PA has been suggested
to have a dual effect. TPA knockout mice exhibit delayed
onset of EAE, but the symptoms were more severe and
recovery was reduced [26]. This finding suggests that t-PA
could have deleterious effects on the initiation of EAE. We
found a borderline significance for the protective effect of the
TPA D/D genotype in MS patients. The net release rate of t-
PA in vivo is significantly higher in the presence of the TPA
I/I genotype compared to carriers of the D allele [9].
The increase in plasma t-PA is related to the appearance
of EAE symptoms in rats [27]. In the brain, t-PA is localized
in the endothelium within regions of neuroinflammation.
Monocyte diapedesis through the BBB depends on t-PA
activity, which can induce the breakdown of the tight-
junction protein occludin, leading to an increase in the
permeability of the interface between the blood and the brain,
the neurovascular unit (NVU), and subsequent monocyte
infiltration into the CNS [28].
Fibrinolysis is generally regulated by the balance between
plasminogen activators and inhibitors. Although t-PA and
PAI-1 are not the only players in this process, they are
among the most important, and the combination genotype
is associated with higher PAI-1 and lower t-PA levels, which
could be protective against the deleterious effect of t-PA on
BBB disruption and lymphocyte infiltration in the brain. The
4G/4G D/D combination, which was not common among
MS patients (6.6%) or controls (8.3%), had the protective
OR, but was not significant.We found a significantly harmful
effect of the combination of the PAI-1 5G/5G genotype and
TPA I allele on MS susceptibility. A reasonable explanation
could be that the potentially higher t-PA levels and lower
PAI-1 levels in carriers of the 5G/5G and I alleles favor the
proteolytic function of t-PA. We did not find any association
of the analyzed polymorphisms with clinical parameters or
the course of the disease. This finding suggests that the
proteolytic function of t-PA and its regulation by its major
inhibitor is more important for MS onset than its role in fib-
rinolysis. Because t-PA is biochemically linked to the matrix
metalloproteinase (MMP) axis of extracellular proteolysis,
it could be important for future studies to examine the
relationship between t-PA andMMPs, at the level of the gene-
gene interaction or on the level of the functional interaction,
which might include the inflammatory cells that infiltrate the
brain through the disrupted BBB.
Although the role of fibrinolysis and extracellular pro-
teolysis has been described in both EAE and MS, this
study is among the first to analyze the insertion/deletion
polymorphisms in PAI-1 and TPA genes in the context of
MS. Validation of our results in other populations and larger
sample sizes is needed.
5. Conclusion
In conclusion, we found a significantly harmful effect of the
PAI-5G/5G genotype on MS in both a study cohort and
meta-analysis. A more significant effect on MS susceptibility
compared to separate gene analysis was shown for the
combination of the PAI-1 5G/5G genotype and TPA I allele.
As shown for the other gene loci in MS, these results indicate
the importance of gene-gene interactions in complex diseases
such as MS.
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